This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the landscape of Novo Nordisk's (NVO) Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults with Type 2 diabetes

Ticker(s): NVO

Who's the expert?

Institution: UT Southwestern Medical Center

  • Board-certified endocrinologist, Professor of medicine, and Director of the Diabetes Clinic at UT Southwestern Medical Center and Parkland Hospital.
  • Currently manages 200 patients with Type 1 Diabetes and 10 patients that use the Omnipod System.
  • Clinical research interests include diabetes management, prevention, and novel treatments while serving as the chair of Biomedical research.

Interview Goal
This call will focus on the current standard of care and the efficacy of Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec from the ONWARDS 3 Randomized Clinical Trial by Novo Nordisk

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.